UroGen Pharma Ltd. (URGN) - חוב לטווח ארוך להון

The verified price history on the GURU.Markets platform chart demonstrates the metrics for UroGen Pharma Ltd. (URGN), where the long-term debt-to-equity ratio is 0.00. Stable cash flow is driven by the demand for the primary drug. The business relies on the implementation of slow-release component systems to minimize procedures. A synergistic effect is achieved through partnerships with specialized centers for the licensing of innovative gels.

This ratio compares liabilities with a maturity of over one year to equity, determining the extent to which long-term financing depends on external borrowings. By analyzing the level of long-term debt load relative to equity, an investor assesses the financial autonomy of UroGen Pharma Ltd. (URGN) when implementing green initiatives for production modernization and the introduction of safe chemical disposal, which requires stable liability management without the risk of excessive leverage.